MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar...

Rare Skin Disorders Market: Key Insights into Future Outlook and Trends of Pemphigus Vulgaris, Epidermolysis Bullosa, Palmoplantar Pustulosis, and Prurigo Nodularis | DelveInsight New York, USA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Rare Skin Disorders Market: Key Insights into Future Outlook and Trends of Pemphigus Vulgaris, Epidermolysis Bullosa, Palmoplantar Pustulosis, and...